| About Philogen |
| |
Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders.....>>
|
| |
| About Philochem |
| |
|
Philochem is a fully owned daughter company of Philogen and represents the Discovery Unit of the Philogen group.
Philochem is based in Otelfingen (Zurich, Switzerland).>>
|
|
|
| Recent News |
 |
|
Siena (Italy),
January 3rd, 2013
Philogen S.p.A. announces Worldwide Licensing Agreement with Pfizer Inc. for Dekavil, an Investigational Immunoregulatory Therapy for Autoimmune Diseases.
Please download the
Press Release.
|
|
|
| Upcoming Events |
 |
|
Madrid (Spain)
June 15th, 2013
Philogen are pleased to announce that a poster presentation by Prof. Galeazzi (University Hospital of Siena) and other clinical collaborators of the company will be displayed at EULAR in Madrid on June 15th 2013. The emerging Phase I clinical trial data for the product 'Dekavil', partnered with Pfizer Inc, will be presented. The title of the poster is: DEKAVIL (F8-IL10): A NOVEL ANTI-INFLAMMATORY IMMUNOCYTOKINE FOR THE TREATMENT OF RHEUMATHOID ARTHRITIS (Poster number SAT0108).
|
|
